Week in Review: ZAI Lab to Develop BMS Liver Cancer Drug in China

ZAI Lab of Shanghai in-licensed China rights to a liver cancer drug candidate from Bristol-Myers Squibb; Concord Medical, a company that operates radiotherapy and imaging centers in China, will pay $40 million to acquire a Singapore hospital from Fortis; Sinophi of the UK will be the exclusive distributor of Advanced Oncotherapy's LIGHT proton beam systems in China; a China Ebola vaccine developed by Beijing Institute of Biotechnology and Tianjin CanSino reported positive data from a Phase I trial; CASI Pharma of Delaware begun a China Phase II trial of its lead molecule in triple-negative breast cancer; Critical Diagnostics of San Diego received CFDA approval to market its heart failure diagnostic in China; CardioKinetix, a California medical device company, reported positive results from a three-month China trial of its minimally invasive heart failure treatment; WuXi PharmaTech announced the CFDA accepted an IND filing of WuXi MedImmune's novel anti-IL6 monoclonal antibody for rheumatoid arthritis; and China's UniTao Pharma postponed plans to open a US manufacturing plant in Petersburg, Virginia. More details.... Stock Symbols: (NYSE: BMY) (NYSE: CCM) (LON: AVO) (NSDQ: CASI) (NYSE: WX) Share this with colleagues: // //